Olga Gherbovet

Title: Olga Gherbovet: Inventor in Therapeutic Research

Introduction

Olga Gherbovet is an inventor associated with Saint-Hilaire, France, and Rappta Therapeutics Oy. Her patent work concerns chemical compounds designed to modulate protein phosphatase 2A (PP2A), a research area with potential relevance to several diseases.

Latest Patents

The available information lists 1 patent associated with Gherbovet: “Substituted Cyclic Modulators of Protein Phosphatase 2A (PP2A) and Methods Using Same.” The disclosure describes chemical modulators of PP2A and their potential use in treating, preventing, or ameliorating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft-versus-host disease, chronic obstructive pulmonary disease, non-alcoholic fatty liver disease, abdominal aortic aneurysm, chronic liver disease, heart failure, neurodegenerative disease, and cardiac hypertrophy.

Career Highlights

Gherbovet’s listed patent reflects work on therapeutic research and the development of compounds that may affect PP2A activity. The disclosure identifies a broad range of potential medical applications, though a patent’s stated uses do not by themselves establish clinical effectiveness or approval.

Collaborations

The patent information names George L. Trainor and Maria Obdulia Rabal Gracia as Gherbovet’s coworkers. The work is associated with Rappta Therapeutics Oy.

Conclusion

Olga Gherbovet’s listed invention focuses on substituted cyclic compounds that modulate PP2A and their potential therapeutic applications, highlighting her connection to drug-discovery research at Rappta Therapeutics Oy.